Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.40 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337989 | 0.92 | SRD5A2 (0.41) | MAOBSRD5A2MEN1NPC1RAB9A | |
| SCHEMBL5344531 | 0.85 | GHSR (0.38) | MAOBSRD5A2MEN1NPC1RAB9A | |
| SCHEMBL5339288 | 0.81 | MAOB (0.38) | MAOBSRD5A2MEN1NPC1RAB9A | |
| SCHEMBL6575073 | 0.80 | SIRT2 (0.49) | HTR6SIRT2 | |
| SCHEMBL28131735 | 0.79 | SRD5A2 (0.48) | MAOBSRD5A2MEN1NPC1RAB9A | |
| SCHEMBL5340172 | 0.77 | GHSR (0.36) | MAOBSRD5A2LTB4RLTB4R2PPARG | |
| SCHEMBL5339384 | 0.77 | HTR1D (0.48) | MAOBMEN1KMT2ASIRT2 | |
| SCHEMBL5332724 | 0.75 | ALDH1A1 (0.52) | MAOBSIRT2 | |
| SCHEMBL5341756 | 0.74 | SIRT2 (0.38) | MAOBSRD5A2NPC1RAB9ASIRT2 | |
| SCHEMBL18549460 | 0.72 | PARP10 (0.50) | MAOBSRD5A2MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202255-B2 | Substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-04-10 | — | — | US | disclosed |
| EP-1587810-B1 | NOVEL SUBSTITUTED 1,4|BENZODIOXINO 2,3-E|ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-02-23 | — | — | US | disclosed |
| EP-1587810-A1 | NOVEL SUBSTITUTED 1,4]BENZODIOXINO 2,3-E]ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004037831-A1 | NOVEL SUBSTITUTED[1,4]BENZODIOXINO[2,3-E]ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | CYP11B2, CYP2F1, CYP3A43 | MAOB 71/4885SRD5A2 186/4885MEN1 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.